Oliver Hasler, executive chairman of PYX Resources, presents 1H24 Results. Watch the interview here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Well they sold 2.6 million and got a good price for the lot, that is how desperate the mm's were for stock at the open
Well they are not my sales but somebody has completely bailed out the mm's selling 1.6 million and limits have totally flipped as you would expect
12 million volume is high looks like a decent buyer is hoovering up big chunks. Would like to know why?
Stalicla could potentially be buying some stock in the background ??
Cheaper for them to takeover TCF than to continue with 'the deal' IF SFX-01 test results were good
Pure speculation of course but a takeover now could save them a chunk of money down the line
So what is driving this, massive trades for this normally quiet stock, millions on offer and now just 150k at full 1p
Inclined to ride my trade a bit longer here when somebody else is buying size
THERACRYF PLC will be holding the meeting Research and Development Update tomorrow at 13th Jun 2024 at 9:30am BST.
Investor Meet Company
Might get some upward movement after that 500k at 0.94p and 300k at 0.98p mm's still refuse to play and narrow the spread
Spread as always remains ridiculous and online 0.825-0.94p currently is only a little better.
Breaking 1p today would be nice, and it seems that someone has taken a little nibble this morning. We got pulled down on very little volume and there is lots of news that should be coming out in the next few months. I am looking forward to the R&D presentation next Thursday.
Obviously, the big re-rate would come from an amicable resolution to the ongoing Stalicla saga, and I remain optimistic that TCF will receive the $500k due for completion of the Phase 1 trials in due course. The latest news from Stalicla themselves, dated May 8th, still suggests that they still plan for STP-1 and, more importantly for us, STP-2 to enter Phase 2 this year. This is published by Stalicla and is viewable on their own website. Before Phase 2 trials can begin, IND has to be approved by the FDA, and this approval for STP-2 leads to a further $5m payment to TCF.
Will we break a penny tomorrow ????
Cannot even buy 50000 at 0.9p atm so it's a squeeze until some sell to help out the mm's
The spreads in everything I hold atm are ridiculous. 90% of the time when there's buying all the mm's do is increase the offer not the bid and widen the spreads, no wonder the penny markets are so poor atm with spreads like this
Decent amount of buying the past few days. Volume picking up, insider buying, R&D presentation next week, cash into 2026. MMs are clearly short on stock and worked the share price down to fill the First Equity Limited purchase. Wide advertised spread and this morning we have moved hard on next to no volume.
All we need now is news to drop about Stalicla paying the money that is due and we'll fly. Not sure when this will drop, but with each passing day we get closer to news.
I did some damage buying max online lots this afternoon. Think it closed NT to buy even 50k at 0.8p with 1 mm left on it so it will move in the morning or it should
I'll sleep a lot better when the sp quadruples :-)
I'm in Thailand so it looks like I can't sleep when I post
4 million shares? Blimey do you not have sleepless nights about your investment? I did agree with your thoughts here after the Stalicla deal was announced, thought this looked a great opportunity but I don’t think that now. I hope you can recover your money at least, it’s possible if only the Stalicla deal delivers.
I don’t think I’ve ever done well on any AIM shares, they all seem very dubious companies to me.
I don’t have any money in any shares at present, I dip in and out of Aviva to get the impressive dividends and buy/sell Flutter when the prices look right. I feel I missed out big time after the Covid crash, I spent all my savings just months earlier on a new car, new kitchen and bathroom. Had I pumped that money into shares like William Hill who I was invested in, I could have easily increased my money fivefold.
I'm just having a moan, I'm confident they will deliver and still holding over 4m shares...
The recent acquisition makes perfect sense to me and they know what they have picked up having worked at Chronos.
Stalicla doing deals with some big pharma names as well as TCF should open some doors for the newly acquired candidates for binge eating, fatigue and anxiety (something as a share holder I can relate to ;)
Well someone's keen - William Black / Armstrong Investments added c.5m shares yesterday. Now holding 5.9%.
At this point I'm not convinced Huw could make a success of a Pharmacy in a city full of sick people with no other Pharmacies :-)
Helen might save the day here
Agree rebarm, a competant board on display there. They are clearly not the typical AIM lifestyle suits some would like to make them out to be. They have however had a run of bad luck - first the COVID trial result (which in hindsight was always doomed to failure, big pharma wanted everone to get their 'vaccines' so no interest in actual treatments), then Juvenescence changng strategy and now Stalicla seemingly dragging their heels on the milestone payment.
On the other hand this is clearly priced in at a £2m market cap!
And so well worth a gamble on the Stalicla situation being resolved at some point this year.
"Imagine a small AIM company spending millions developing a capsule without knowing what it does lol "
Umm.. how exactly would you expect any pharma to conduct clinical trials without first developing the prospective drug? Bit of a catch-22?
TCF have spent millions developing a medical grade Sulforaphane tablet and then a capsule (and wages/ bonuses)...
We will eventually find out if it has a meaningful benefit to the medical industry...
Horse before the cart imo but at this stage it will either pay handsomely or it was all for F all.
Imagine a small AIM company spending millions developing a capsule without knowing what it does lol
Huw has run this into the ground but he could still get lucky so holding on
Helen seemed switched on which is encouraging
And we’ve hit another year’s low sp!
Fwiw
I noticed from Stalicla updated website ? That the pipeline STP2 /SFX-01 has progressed to P2 and the our new name noted
"STP2, or SFX-01, is a stabilized synthetic form of sulforaphane for which STALICLA has acquired the rights for neurodevelopment disorders worldwide from TheraCryf (formerly known as Evgen Pharma) in October 2022.
STP2 is being advanced as a precision medicine treatment candidate for a subgroup of patients with ASD called Phenotype 2. Phase 1 data is currently being evaluated to support further clinical development into phase 2 trials."